Risk of febrile neutropenia in very elderly patients aged ≥80 years receiving their first cycle of R-CHOP regimen: a nationwide real-world study in Japan

Kensuke Matsuda; Taisuke Jo; Arika Shimura; Akira Honda; Kazuki Taoka; Yosuke Masamoto; Hiroki Matsui; Kiyohide Fushimi; Hideo Yasunaga; Mineo Kurokawa

doi:10.1111/bjh.18028

Risk of febrile neutropenia in very elderly patients aged ≥80 years receiving their first cycle of R-CHOP regimen: a nationwide real-world study in Japan

Br J Haematol. 2022 May;197(3):e37-e41. doi: 10.1111/bjh.18028. Epub 2022 Jan 3.

Authors

Affiliations

¹ Department of Haematology and Oncology, Graduate School of Medicine, Tokyo, Japan.
² Department of Health Services Research, Graduate School of Medicine, Tokyo, Japan.
³ Department of Clinical Epidemiology and Health Economics, School of Public Health, Tokyo, Japan.
⁴ Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan.
⁵ Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, Japan.

PMID: 34978068
DOI: 10.1111/bjh.18028

No abstract available

Keywords: antimicrobial prophylaxis; febrile neutropenia; granulocyte colony-stimulating factor; malignant lymphoma; rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone (R-CHOP).

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols* / adverse effects
Cyclophosphamide / adverse effects
Doxorubicin / adverse effects
Febrile Neutropenia* / chemically induced
Granulocyte Colony-Stimulating Factor / adverse effects
Humans
Japan / epidemiology
Prednisolone
Prednisone / adverse effects
Rituximab / adverse effects
Vincristine / adverse effects

Substances

Granulocyte Colony-Stimulating Factor
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisolone
Prednisone

Supplementary concepts

VAP-cyclo protocol